在非洲高血压的药物遗传学和局限性 - 专注于ACE,AGTR1和CYP2C9基因
Rejoice T Gomera1, Wesley van Hougenhouck-Tulleken2, Sarel J Brand3
1Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Pretoria, 0028, Pretoria, South Africa. u15286054@tuks.co.za.
Journal of human hypertension
|February 21, 2026
概括
非洲的高血压治疗受到遗传变异性和研究中的代表性不足的阻碍. 根据ACE,AGTR1和CYP2C9等遗传标记量身定制血压药物可以改善非洲人口的结果.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 遗传学 遗传学 是一个
背景情况:
- 全球有超过10亿人患有高血压,血压控制率不佳,特别是在撒哈拉以南非洲.
- 个体间的遗传变异性影响抗高血压药物的疗效,需要个性化治疗方法.
- 参与高血压的关键基因 (ACE,AGTR1,CYP2C9) 已知影响非非洲人群药物反应的单核酸变异.
研究的目的:
- 审查非洲人群中高血压的药物遗传情景,重点关注ACE,AGTR1和CYP2C9基因.
- 强调将药物遗传学发现应用于非洲人口的挑战,包括有限的研究和基因组数据.
- 强调研究和基础设施的必要性,以推进非洲高血压的精准医学.
主要方法:
- 与高血压相关的药物遗传研究的文献综述.
- 对ACE,AGTR1和CYP2C9.9的基因药物相互作用的分析.
- 检查人口特异性数据缺口和非洲祖先的基因组变异性.
主要成果:
- 现有的高血压的药物遗传数据主要来自非非洲人群,限制了直接适用性.
- 非洲种群表现出显著的基因组变异性,需要专门的研究来确定特定于种群的遗传标记.
- 挑战包括有限的药物遗传测试实施和在全球基因组数据集中的代表性不足.
结论:
- 在非洲,高血压的精准医学需要解决基因组数据中的代表性不足问题,并实施药物遗传学测试.
- 对不同非洲人群中基因药物相互作用的进一步研究对于优化抗高血压疗法至关重要.
- 发展研究基础设施对于推进量身定制的高血压治疗和改善非洲心血管和结局至关重要.
相关概念视频
01:27Principles of Pharmacogenetics: Types of Genetic Variants
29
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
29
01:29Pharmacogenomics: Identification of New Drug Targets
29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
24
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24
01:27Pharmacogenetics of Drug Metabolism: Overview
31
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
31
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
30
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
27
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27